Biogen (BIIB) Share-based Compensation (2009 - 2026)

Biogen (BIIB) has reported Share-based Compensation for 18 consecutive years, with $84.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 3.7% year-over-year to $84.0 million; the TTM figure through Mar 2026 stood at $293.8 million (down 1.87% YoY), while the FY2025 annual figure was $290.8 million, changed 0.14% from the prior year.
• Share-based Compensation came in at $84.0 million for Q1 2026 at Biogen, up from $59.6 million in the prior quarter.
• The five-year high for Share-based Compensation was $84.0 million in Q1 2026, with the low at $54.9 million in Q4 2023.
• Average Share-based Compensation over 5 years is $69.7 million, with a median of $71.5 million recorded in 2023.
• Across the five-year window, Share-based Compensation jumped 36.79% in 2024 and slipped 20.64% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $67.2 million in 2022, then declined by 18.3% to $54.9 million in 2023, then surged by 36.79% to $75.1 million in 2024, then decreased by 20.64% to $59.6 million in 2025, then surged by 40.94% to $84.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $84.0 million, $59.6 million, and $75.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.